Artios Pharma has in-licensed its first nuclease drug development program from Masaryk University as part of a collaborative effort to develop novel cancer therapies targeting DNA nucleases.

Target Information

Artios Pharma, a prominent player in the DNA Damage Response (DDR) sector, focuses on creating innovative cancer treatments. Recently, the company announced the in-licensing of its first nuclease drug development program from Masaryk University in the Czech Republic, as part of a research collaboration initiated in June 2017. This collaboration aims to identify and develop novel cancer therapies by targeting DNA nucleases that play a crucial role in DDR.

Niall Martin, the Chief Executive Officer of Artios Pharma, expressed his enthusiasm regarding this milestone, stating that the in-licensed program has the potential to become a groundbreaking, first-in-class DDR-targeted treatment for cancer. This development not only enhances Artios's current pipeline but also reinforces its leadership position in the DDR landscape.

Industry Overview

The Czech Republic, known for its robust research infrastructure, has emerged as a key player in the biotechnology sector, particularly in cancer research and treatment innovations. With institutions like Masaryk University leading the charge,